Development and validation of a sensitive LC MS/MS method for the measurement of the checkpoint kinase 1 inhibitor prexasertib and its application in a cerebral microdialysis study
暂无分享，去创建一个
[1] C. Stewart,et al. Development and validation of LC-MS/MS methods for the measurement of ribociclib, a CDK4/6 inhibitor, in mouse plasma and Ringer's solution and its application to a cerebral microdialysis study. , 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[2] R. Gilbertson,et al. Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study , 2015, Cancer Chemotherapy and Pharmacology.
[3] P. Savage,et al. Development and economic trends in cancer therapeutic drugs: a 5-year update 2010–2014 , 2015, British Journal of Cancer.
[4] C. Stewart,et al. Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[5] Mallikarjun Patil,et al. Checkpoint kinase 1 in DNA damage response and cell cycle regulation , 2013, Cellular and Molecular Life Sciences.
[6] R. Nirogi,et al. Approach to reduce the non-specific binding in microdialysis , 2012, Journal of Neuroscience Methods.
[7] Yuan-Qing Xia,et al. Systematic LC-MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thought-out chromatography. , 2010, Biomedical chromatography : BMC.